Celcuity (CELC) Stock: Buy, Sell, or Hold?
CELC - Celcuity Inc. Common Stock
$61.56
1.56 (2.60%)
▲
5d:
+2.77%
30d:
-26.8%
90d:
-30.31%
HOLD
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 11, 2026
19d
Get Alerted When CELC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CELC shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: CELC shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: CELC is currently trading at $61.56, which is considered oversold relative to its 30-day fair value range of $63.47 to $81.96. From a valuation perspective, the stock is trading at a discount (Forward PE: -769.5) compared to its historical average (125.4). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CELC is in a downtrend. Immediate support is located at $53.54, while resistance sits at $69.08.
Market Sentiment: CELC scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $156.91 (+154.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CELC is in a downtrend. Immediate support is located at $53.54, while resistance sits at $69.08.
Market Sentiment: CELC scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $156.91 (+154.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$63.47 -
$81.96
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
95.2%
Protect Your Profits
Holding CELC? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (68/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 154.9% below Wall St target ($156.91)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Bottoming setup, but lagging the sector by 16% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$63.47 -
$81.96
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$53.54
Resistance Level
$69.08
Current Trend
Downtrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-769.50
Wall Street Target
$156.91
(+154.9%)
PE vs Historical
-769.5 vs 125.4
CHEAP
Share & Embed Analysis
Last updated: October 21, 2026 11:07 PM ET
Data refreshes hourly during market hours. Next update: 12:07 AM
Data refreshes hourly during market hours. Next update: 12:07 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CELC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$295 | 56 HOLD |
|
REGN
Regeneron Pharmaceutical… |
BUY
28 analysts |
$864 | 47 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
STRONG BUY
20 analysts |
$31 | 71 BUY |
|
PRAX
Praxis Precision Medicin… |
STRONG BUY
20 analysts |
$650 | 50 HOLD |
|
ELVN
Enliven Therapeutics Inc. |
STRONG BUY
14 analysts |
$74 | 63 BUY |
Advanced CELC Option Strategies
Professional options setups generated by AI based on today's CELC price and gamma walls.
